<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30055" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Thiazide Diuretics</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Akbari</surname>
            <given-names>Pegah</given-names>
          </name>
          <aff>American Un of Integrated Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khorasani-Zadeh</surname>
            <given-names>Arshia</given-names>
          </name>
          <aff>Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pegah Akbari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arshia Khorasani-Zadeh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30055.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Thiazide diuretics are an FDA-approved class of drugs that inhibit the reabsorption of 3% to 5% of luminal sodium in the distal convoluted tubule of the nephron. By doing so, thiazide diuretics promote natriuresis and diuresis. Three thiazide diuretics are the most commonly used: hydrochlorothiazide (HCTZ), chlorthalidone, and indapamide. HCTZ and chlorthalidone are FDA-approved for clinical use in the management of primary hypertension. HCTZ and chlorthalidone are also FDA-approved for clinical use in adjunctive therapy in edema that is associated with chronic heart failure (CHF), hepatic cirrhosis, corticosteroids, and estrogen therapy. Indapamide is FDA-approved for the treatment of salt and fluid retention associated with CHF and in the management of primary hypertension as either the sole treatment or in conjunction with other antihypertensive drugs. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, toxicity, and monitoring of thiazide diuretics so providers can direct patient therapy where they are indicated as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess the mechanism of action of thiazide diuretics.</p></list-item><list-item><p>Identify the indications for various agents in the thiazide diuretic drug class.</p></list-item><list-item><p>Evaluate&#x000a0;the adverse events and contraindications associated with the thiazide diuretic class of drugs.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination to properly use thiazide diuretics to improve patient outcomes in the varied scenarios where they are effective.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30055&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30055">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30055.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Thiazide diuretics are an FDA-approved class of drugs that inhibit the reabsorption of 3% to 5% of luminal sodium in the distal convoluted tubule of the nephron. By doing so, thiazide diuretics promote natriuresis and diuresis. Three thiazide diuretics are commonly used: hydrochlorothiazide (HCTZ), chlorthalidone, and indapamide. HCTZ and chlorthalidone&#x000a0;are FDA-approved for clinical&#x000a0;use in the&#x000a0;management of primary hypertension. Clinicians use these agents as either the sole modality of treatment or in conjunction&#x000a0;with other antihypertensive drugs to effectively increase therapeutic response in severely hypertensive patients. HCTZ and chlorthalidone&#x000a0;are also FDA-approved for clinical&#x000a0;use in&#x000a0;adjunctive therapy in edema that is associated with chronic heart failure (CHF), hepatic cirrhosis, corticosteroids,&#x000a0;and estrogen therapy. These agents are also&#x000a0;used&#x000a0;to manage&#x000a0;edema caused by various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis,&#x000a0;and chronic renal failure. Indapamide is FDA-approved for the treatment of salt and fluid retention associated with CHF and in the&#x000a0;management of primary hypertension as either the sole treatment or in conjunction&#x000a0;with other antihypertensive drugs. Thiazide diuretics are also indicated for use (although not FDA-approved) for nephrolithiasis, osteoporosis, and diabetes insipidus.<xref ref-type="bibr" rid="article-30055.r1">[1]</xref><xref ref-type="bibr" rid="article-30055.r2">[2]</xref></p>
      </sec>
      <sec id="article-30055.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Thiazide diuretics exert their diuretic effect via blockage of the sodium-chloride (Na/Cl) channel in the proximal segment of the distal convoluted tubule (DCT). When the Na/Cl channel is blocked, decreased levels of sodium cross the luminal membrane, thus decreasing the action of the sodium-potassium&#x000a0;(Na/K) pump and decreasing Na and water passage to the interstitium.<xref ref-type="bibr" rid="article-30055.r3">[3]</xref>&#x000a0;The activation method of thiazide diuretics causes a change in Na concentration distal to the DCT. Subsequently, ionic channels and pumps work to balance disrupted Na levels. This secondary change to balance Na levels produces many adverse effects. The MOA and its effects on the nephron are more thoroughly discussed below and are referred to in the adverse effects section. The blockage of the Na/Cl channel causes an increase in sodium and water retention in the lumen and a decrease in Na in the DCT. At the same time, blockage of the Na/Cl channel increases the flow of ions through the Na/Ca channel, resulting in increased calcium reabsorption into the interstitium in exchange&#x000a0;for Na return to the DCT. Inhibition of the Na/Cl channel in the proximal segment of the&#x000a0;DCT results in increased delivery of sodium to the distal segment of the&#x000a0;DCT and collecting tubule. This increased Na increase causes the aldosterone-sensitive Na/K pump to increase sodium reabsorption in the principal cells. This exchange increases Na transfer into the interstitium and K transfer into the collecting tubules and lumen. This loss of K then causes intercalated cells in the collecting tubule to increase K reabsorption via the K/H+ pump, which is also aldosterone-mediated. Through aldosterone-mediated sodium retention precipitated by an increased Na flow to the collecting tubule, the collecting tubule exhibits increased reabsorption of Na and excretion of both K and H ions into the urine.<xref ref-type="bibr" rid="article-30055.r4">[4]</xref></p>
      </sec>
      <sec id="article-30055.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Thiazide diuretics are administered orally as tablets. Patients should take these agents in the morning with food. HCTZ and chlorthalidone have different dosing requirements for their indicated FDA use listed above. Generally, for hypertension treatment, both drugs require a lower dosage, starting at 25 mg daily, and may be increased to 50 mg or 100 mg, respectively. The dosage should be increased based on the individual therapeutic needs of the patient. For patients with fluid buildup and edema, dosing starts at 50 mg to 100 mg and 50 to 200 mg,&#x000a0;respectively.<xref ref-type="bibr" rid="article-30055.r5">[5]</xref><xref ref-type="bibr" rid="article-30055.r6">[6]</xref><xref ref-type="bibr" rid="article-30055.r7">[7]</xref></p>
      </sec>
      <sec id="article-30055.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of thiazide diuretics stem from the ionic imbalance caused due to the initial Na loss in the DCT.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hypokalemia.</bold>&#x000a0;Most widely recognized, the first adverse effect of thiazide diuretics is hypokalemia. As discussed above, hypokalemia is a&#x000a0;sequela of the aldosterone-mediated actions of the Na/K pump in the collecting tubule. Hypokalemia can be life-threatening and requires monitoring during the first 2-3 weeks of HCTZ therapy.</p>
          </list-item>
          <list-item>
            <p><bold>Hyponatremia. </bold>The MOA of thiazide diuretics is to decrease sodium reabsorption and, therefore, decrease fluid reabsorption; this directly causes decreased levels of circulating sodium.&#x000a0;If hyponatremia were to occur, it would happen during the first 2 to 3 weeks of therapy; after this time, the patient is in a new steady state in which further sodium and water losses do not occur.</p>
          </list-item>
          <list-item>
            <p><bold>Metabolic alkalosis.</bold>&#x000a0;Patients on thiazide diuretics may experience a hypokalemic metabolic alkalosis due to increased aldosterone-mediated K and H ions excretion in the intercalated cells of the collecting tubule.</p>
          </list-item>
          <list-item>
            <p><bold>Hypercalcemia.</bold>&#x000a0;Thiazides reduce urine calcium levels and increase blood calcium by increasing calcium reabsorption from the luminal membrane into the interstitium in exchange for sodium. However, if indicated, this effect of thiazide diuretics makes thiazides useful for nephrolithiasis and osteoporosis treatment. Decreased urinary calcium decreases stone development in the kidney, and increased blood calcium benefits patients with osteoporosis and promotes bone health.</p>
          </list-item>
          <list-item>
            <p><bold>Hyperglycemia</bold>. Thiazide diuretics cause hypokalemia; at the level of the pancreatic B cells, this hypokalemia causes hyperpolarization of the B cell and decreases insulin secretion. Decreased K in the interstitium keeps the K channels open for an extended time, which causes the hyperpolarization of the cell. This hyperpolarization does not allow the voltage-gated calcium channels to open. When intracellular calcium does not increase through calcium influx via the voltage-gated calcium channels, exocytosis of insulin granules does not occur in the pancreatic B cells.</p>
          </list-item>
          <list-item>
            <p><bold>Hyperuricemia</bold>. Thiazide diuretics cause hyperuricemia and increase the risk of developing gout. Thiazides directly increase urate reabsorption in the proximal tubule using the OAT 1 anion exchanger on the basolateral membrane and the Luminal membrane's OAT 4 urate anion exchanger. At the OAT 1 exchanger, thiazides enter the proximal convoluted tubule, replacing urate for an anion, increasing urate in the interstitium. The OAT 4 exchanger exchanges thiazides for urate in the lumen, causing increased urate in the proximal convoluted tubule that then crosses the basolateral membrane, increasing urate in the interstitium.</p>
          </list-item>
          <list-item>
            <p><bold>Hyperlipidemia</bold>. The mechanism of hyperlipidemia with thiazide treatment is unclear. However, it appears to be an acute response to high-dose thiazide treatment.</p>
          </list-item>
          <list-item>
            <p><bold>Sulfonamide allergy</bold>. Thiazide diuretics are sulfa-containing drugs. Patients with sulfa allergies who take thiazides may experience headaches, rash, hives, swelling of the mouth and lips, wheezing or trouble breathing, asthma attacks, and anaphylaxis.</p>
          </list-item>
        </list>
        <p>Adverse effects of taking these medications also include a possible increased risk of developing acute pancreatitis. T hypothesized that thiazides have a toxic effect on the pancreas and cause increased pancreatic secretions and pancreatic ischemia. If the clinician observes symptoms of acute pancreatitis, the patient must immediately stop the use of the thiazide diuretic, and they should not be re-prescribed to this medication.<xref ref-type="bibr" rid="article-30055.r8">[8]</xref><xref ref-type="bibr" rid="article-30055.r9">[9]</xref><xref ref-type="bibr" rid="article-30055.r10">[10]</xref></p>
      </sec>
      <sec id="article-30055.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Thiazide diuretics are contraindicated for use in&#x000a0;patients with anuria and sulfonamide allergies.</p>
      </sec>
      <sec id="article-30055.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>
<bold>An Evidence-based Approach to Thiazide Diuretics</bold>
</p>
        <p>Besides physicians, thiazide diuretics are monitored by pharmacists and nurses, who collaborate with clinicians as an interprofessional team.&#x000a0;In most cases, a thiazide&#x000a0;is&#x000a0;prescribed for long periods; hence, patient electrolyte levels require monitoring. Also, polypharmacy&#x000a0;must be avoided, especially in the elderly. Patients need education on the adverse effects of these agents and their presentation. The potassium levels must be closely followed for patients with heart problems and susceptibility to arrhythmias. Also, the patient needs to be weighed at each visit to ensure that the fluid overload is resolved. Patients prone to hypokalemia&#x000a0;must receive education on the consumption of foods that are&#x000a0;rich in potassium. Finally, the clinical team needs to follow the patient's lipid levels need to be followed as thiazides cause hyperlipidemia. By utilizing an interprofessional team approach, these adverse events can remain in check, and therapeutic benefits can be maximized.<xref ref-type="bibr" rid="article-30055.r11">[11]</xref><xref ref-type="bibr" rid="article-30055.r12">[12]</xref></p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Thiazide diuretics have been in use for over half a century and are relatively safe and effective&#x000a0;drugs for the treatment of hypertension and heart failure. These drugs are used&#x000a0;in outpatients to manage chronic edema states. The majority of patients do&#x000a0;respond to these agents, and the most common adverse effect reported is hypokalemia. To date, there are only a few reports of arrhythmias in patients taking thiazides.<xref ref-type="bibr" rid="article-30055.r13">[13]</xref><xref ref-type="bibr" rid="article-30055.r14">[14]</xref></p>
      </sec>
      <sec id="article-30055.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30055&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30055">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30055/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30055">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30055.s9">
        <title>References</title>
        <ref id="article-30055.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roush</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Abdelfattah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ernst</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Sica</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Kostis</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1507</fpage>
            <page-range>1507-1515</page-range>
            <pub-id pub-id-type="pmid">30251403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kuznia</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>High Blood Pressure in Children and Adolescents.</article-title>
            <source>Am Fam Physician</source>
            <year>2018</year>
            <month>Oct</month>
            <day>15</day>
            <volume>98</volume>
            <issue>8</issue>
            <fpage>486</fpage>
            <page-range>486-494</page-range>
            <pub-id pub-id-type="pmid">30277729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alon</surname>
                <given-names>US</given-names>
              </name>
            </person-group>
            <article-title>The Effects of Diuretics on Mineral and Bone Metabolism.</article-title>
            <source>Pediatr Endocrinol Rev</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>291</fpage>
            <page-range>291-297</page-range>
            <pub-id pub-id-type="pmid">29806749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pourafshar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alshahrani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soleimani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Thiazide Therapy in Chronic Kidney Disease: Renal and Extra Renal Targets.</article-title>
            <source>Curr Drug Metab</source>
            <year>2018</year>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>1012</fpage>
            <page-range>1012-1020</page-range>
            <pub-id pub-id-type="pmid">29962339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webster</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Silva</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Selak</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Stepien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajapakse</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amarasekara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amarasena</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Billot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de Silva</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Fernando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guggilla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jayawardena</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maulik</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Mendis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mendis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Munasinghe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Prabhakaran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ranasinghe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tisserra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Senaratne</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wijekoon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wijeyasingam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <collab>TRIUMPH Study Group</collab>
            </person-group>
            <article-title>Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Aug</month>
            <day>14</day>
            <volume>320</volume>
            <issue>6</issue>
            <fpage>566</fpage>
            <page-range>566-579</page-range>
            <pub-id pub-id-type="pmid">30120478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexander</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jandoc</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Welk</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fuster</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Thiazide Diuretic Dose and Risk of Kidney Stones in Older Adults: A Retrospective Cohort Study.</article-title>
            <source>Can J Kidney Health Dis</source>
            <year>2018</year>
            <volume>5</volume>
            <fpage>2054358118787480</fpage>
            <pub-id pub-id-type="pmid">30034815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Islam</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>The Art and Science of Using Diuretics in the Treatment of Heart Failure in Diverse Clinical Settings.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2018</year>
            <volume>1067</volume>
            <fpage>47</fpage>
            <page-range>47-65</page-range>
            <pub-id pub-id-type="pmid">29500794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kieboom</surname>
                <given-names>BCT</given-names>
              </name>
              <name>
                <surname>Zietse</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ikram</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hoorn</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Stricker</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Thiazide but not loop diuretics is associated with hypomagnesaemia in the general population.</article-title>
            <source>Pharmacoepidemiol Drug Saf</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>1166</fpage>
            <page-range>1166-1173</page-range>
            <pub-id pub-id-type="pmid">30095199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raffin</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Penniston</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Antonelli</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Viprakasit</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Averch</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Sivalingam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sur</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Nakada</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Pais</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>The Effect of Thiazide and Potassium Citrate Use on the Health Related Quality of Life of Patients with Urolithiasis.</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>200</volume>
            <issue>6</issue>
            <fpage>1290</fpage>
            <page-range>1290-1294</page-range>
            <pub-id pub-id-type="pmid">29913138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gebrehiwet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fitsum</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Russom</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hydrochlorothiazide and risk of hearing disorder: a case series.</article-title>
            <source>J Med Case Rep</source>
            <year>2018</year>
            <month>May</month>
            <day>20</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>135</fpage>
            <pub-id pub-id-type="pmid">29778098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nadal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Channavajjhala</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Clayton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Glover</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical and Molecular Features of Thiazide-Induced Hyponatremia.</article-title>
            <source>Curr Hypertens Rep</source>
            <year>2018</year>
            <month>Apr</month>
            <day>10</day>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>31</fpage>
            <pub-id pub-id-type="pmid">29637415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reboussin</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Griswold</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Guallar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>EPR</given-names>
              </name>
              <name>
                <surname>Polonsky</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thompson-Paul</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vupputuri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task&#x000a0;Force&#x000a0;on&#x000a0;Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>71</volume>
            <issue>19</issue>
            <fpage>2176</fpage>
            <page-range>2176-2198</page-range>
            <pub-id pub-id-type="pmid">29146534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verbrugge</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Editor's Choice-Diuretic resistance in acute heart failure.</article-title>
            <source>Eur Heart J Acute Cardiovasc Care</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>379</fpage>
            <page-range>379-389</page-range>
            <pub-id pub-id-type="pmid">29897275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30055.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arroll</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Should we switch from bendrofluazide to chlorthalidone as the initial treatment for hypertension? A review of the available medication.</article-title>
            <source>J Prim Health Care</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-113</page-range>
            <pub-id pub-id-type="pmid">29530222</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
